CFTR and cystic fibrosis: Kalydeco® (ivacaftor), Orkambi® (lumacaftor/ivacaftor) and Symkevi® (tezacaftor/ivacaftor) were the first treatments authorized in the European Union to target the underlying mechanism of the dysfunctional CFTR protein in cystic fibrosis (Lopes-Pacheco, 2016; Rafeeq and Murad, 2017; Lopes-Pacheco, 2019).